Is Ramipril Really Better Than Other Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction?

American Journal of Cardiology

Volumn 98, Issue 1, 2006, Pages 6-9

  Tu, Karen ^a,b,c   Gunraj, Nadia ^a   Mamdani, Muhammad ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ACUTE HEART INFARCTION; AGED; ARTICLE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; COHORT STUDIES; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; ONTARIO; RAMIPRIL; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745158619     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.01.044     Document Type: Article

References (11)

1. Pilote L., Abrahamowicz M., Rodrigues E., Eisenberg M.J., and Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction. a class effect?. Ann Intern Med 141 (2004) 102-112
2. Humphries K.D., Rankin J.M., Carere R.G., Buller C.E., Kiely F.M., and Spinelli J.J. Co-morbidity data in outcomes research. are clinical data derived from administrative databases a reliable alternative to chart review?. J Clin Epidemiol 53 (2000) 343-349
3. Austin P.C., Daly P.A., and Tu J.V. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 144 (2002) 290-296
4. Levy A.R., Tamblyn R.M., Fitchett D., McLeod P.J., and Hanley J.A. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 15 (1999) 1277-1282
5. Glesby M.J., and Hoover D.R. Survivor treatment selection bias in observational studies. examples from the AIDS literature. Ann Intern Med 124 (1996) 999-1005
6. Mamdani M., Juurlink D.N., Lee D.S., Rochon P.A., Kopp A., Naglie G., Austin P.C., Laupacis A., and Stukel T.A. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients. a population-based cohort study. Lancet 363 (2004) 1751-1756
7. Schneeweiss S., Seeger J.D., Maclure M., Wang P.S., Avorn J., and Glynn R.J. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154 (2001) 854-864
8. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies. development and validation. J Chron Dis 40 (1987) 373-383
9. Hux J.E., Ivis F., Flintoft V., and Bica A. Diabetes in Ontario. determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25 (2002) 512-516
10. Tu K., Mamdani M.M., Kopp A., and Lee D. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Am J Cardiol 95 (2005) 283-286
11. Raasch W., Bartels T., Schwartz C., Hauser W., Rutten H., and Dominiak P. Regression of ventricular and vascular hypertrophy. are there differences between structurally different angiotensin-converting enzyme inhibitors?. J Hypertens 20 (2002) 2495-2504